8-KOther EventsExhibits & Filings

ELI LILLY & Co 8-K Report, Corporate Update (Feb 24, 2023)

Filed February 24, 2023For Securities:LLY

Summary

Eli Lilly and Company (LLY) announced on February 23, 2023, the successful issuance and sale of a substantial debt offering totaling approximately $4 billion. This offering consisted of four tranches of notes with varying maturities and coupon rates: $750 million of 5.000% Notes due 2026, $1 billion of 4.700% Notes due 2033, $1.25 billion of 4.875% Notes due 2053, and $1 billion of 4.950% Notes due 2063. The net proceeds from this offering, estimated at approximately $3.96 billion after underwriting discounts and before other expenses, are expected to provide significant financial flexibility for the company. This substantial capital raise indicates Lilly's strategic intent to strengthen its balance sheet, potentially to fund ongoing research and development, business development activities, or general corporate purposes. Investors should note the long-term nature of some of these notes, particularly the 2053 and 2063 tranches, reflecting the company's long-term financial planning and commitment to growth. The details of the underwriting agreement and the terms of the notes have been filed with the SEC, offering transparency on the transaction.

Key Highlights

  • 1Eli Lilly completed a significant debt offering of approximately $4 billion across four note series with maturities ranging from 2026 to 2063.
  • 2The notes carry fixed interest rates ranging from 4.700% to 5.000% per annum, payable semi-annually.
  • 3The company expects to receive net proceeds of approximately $3.96 billion from this offering.
  • 4The issuance diversifies Lilly's debt structure with long-dated maturities, including notes due in 2053 and 2063.
  • 5The offering was registered on a Form S-3, indicating Lilly's established reporting status and readiness for capital markets transactions.
  • 6The transaction was underwritten by a syndicate of major financial institutions, including J.P. Morgan, Credit Suisse, Goldman Sachs, and Morgan Stanley.

Frequently Asked Questions

While the 8-K filing does not explicitly state the use of proceeds, such a significant debt issuance typically aims to strengthen the company's balance sheet, fund ongoing research and development initiatives, support potential business development activities, or for general corporate purposes. Investors can infer a strategic financial move to enhance Lilly's financial flexibility and capacity for future investments.

The notes have the following terms: 5.000% Notes due 2026 ($750 million), 4.700% Notes due 2033 ($1 billion), 4.875% Notes due 2053 ($1.25 billion), and 4.950% Notes due 2063 ($1 billion). All notes accrue interest at their stated rates semi-annually.

The aggregate principal amount of the notes issued is $3.95 billion ($750 million + $1 billion + $1.25 billion + $1 billion). After deducting underwriting discounts and before estimated offering expenses, the company expects to realize net proceeds of approximately $3.96 billion.

The issuance of long-dated notes (maturing in 2053 and 2063) suggests a strategic approach by Eli Lilly to secure long-term financing at current market rates. For investors, this indicates the company's long-term outlook and commitment to its growth strategies, as it locks in borrowing costs over an extended period. It also implies the company anticipates continued operational strength to service this debt.